Detection by HRM and COLD-PCR-HRM BRAF mutational status in paraffin blocks of melanoma patients

Abstract

Resumen del póster presentado a la European Human Genetics Conference celebrada en Nuremberg (Alemania) del 23 al 26 de junio de 2012.Over 50% of melanoma tumors have BRAF oncogene mutation. In 2011 we have obtained the first results of clinical trials of targeted therapy with molecules that act on BRAF signaling pathways (Ras/Raf/MEK/ERK). Vemurafenib and GSK2118436 showed an increase in overall survival and disease-free in p.V600E BRAF carriers patients. In the coming months, these molecules will be approved for clinical use in Europe. The application of analytical methods of high sensitivity in determining the mutational status of BRAF will be crucial to the imminent clinical application of new drugs, as the results will select patients eligible for or untreated. We have studied the 11 and 15 exons of BRAF by HRM.sequencing, and COLD-PCR-HRM-sequencing in 20 paraffin blocks of melanoma, previously studied by Sanger sequencing. Mutation was detected p.V600E of exon 15 in 9 of them for HRM, and 11 by COLD-HRM, compared to 8 previously detected by sequencing. The sensitivity of such methods as HRM and COLD-PCR-HRM is greater than sequencing. These results should be compared with those obtained by the propose clinical diagnostic tests (eg cobas 4800 BRAF V600 Mutation Test Roche©). Our previous results show the necessary standardization of the methods of detection of somatic mutations, especially in cases where the determined result to apply the therapy to the patient.Peer reviewe